There’s a chemical firm in Surat quietly supplying chemicals most individuals have by no means heard of. A few of these chemicals go into anti-HIV medicine. Others are utilized in battery electrolytes. Some are semiconductor-grade chemicals utilized in superior chip manufacturing.
For many of its listed historical past, the market largely seen it as a pharmaceutical intermediates producer. That notion is now altering.
The firm is trying to construct a multi-segment specialty chemicals platform spanning prescribed drugs, semiconductors, battery chemicals, superb chemicals, and CDMO-style customized synthesis. And the market is starting to recognise that shift.
The inventory has re-rated sharply over the final 18 months as income progress accelerated, margins expanded, and newer verticals advanced from “future optionality” into seen business scale.
The key query is this: Is Acutaas Chemicals constructing a sturdy specialty chemicals franchise with a number of long-term progress engines? Or is the market extrapolating an excessive amount of, too rapidly, from a handful of high-growth verticals
Let’s dive in.
Understanding what Acutaas builds
To grasp Acutaas Chemicals, you first want to grasp why the enterprise is troublesome to classify.
Most chemical firms match neatly into one bucket:
- Commodity chemicals
- Specialty chemicals
- Pharma intermediates
- Contract manufacturing
Acutaas sits someplace between all of them.
Story continues beneath this advert
The firm initially constructed its franchise round superior pharmaceutical intermediates utilized in APIs for anti-retroviral therapies, oncology, and high-value specialty therapies.
Over time, administration realised that the actual aggressive benefit was not merely the finish market. It was the underlying chemistry functionality itself.
That functionality is now being prolonged into a number of adjoining industries, together with battery chemicals, semiconductor chemicals, CDMO, customized synthesis, and area of interest specialty supplies.
Enterprise segments
Increasing chemical capabilities
Story continues beneath this advert
As we speak, the firm broadly experiences enterprise below two main verticals:
Pharma (88% of FY26 income)
Specialty chemicals (12% of FY26 income)
The combine between these segments has fluctuated over time, however specialty chemicals have structurally elevated from lower than 1% of income in FY21 to 13% in FY26.
Key segment-wise income combine
Supply: This fall FY26 Investor Presentation
What makes this construction attention-grabbing is that each verticals depend on the identical underlying functionality: advanced chemistry execution.
Monetary efficiency
Supply: This fall FY26 Investor Presentation
The pharma enterprise: From intermediates to CDMO
Story continues beneath this advert
Pharma stays the foundational cash-flow engine for Acutaas Chemicals, contributing 88% of FY26 income.
Traditionally, the firm constructed its franchise round superior pharmaceutical intermediates used throughout a number of therapeutic classes. As we speak, it exports to greater than 55 nations and has constructed long-standing relationships throughout regulated and semi-regulated markets.
What makes this enterprise structurally enticing is buyer stickiness.
As soon as a pharmaceutical firm qualifies a provider for a crucial intermediate, switching turns into operationally and regulatorily troublesome.
However the larger story at the moment is CDMO. Administration has guided that the CDMO enterprise alone may doubtlessly attain Rs 1,000 crore in income by FY28.
Story continues beneath this advert
Acutaas already provides superior intermediates utilized in the manufacturing of Darolutamide, the key API behind Bayer and Orion’s blockbuster prostate most cancers drug Nubeqa®, whose world gross sales proceed to scale quickly.
Bayer AG – ‘Nubeqa’ associated KPIs
Supply: Bayer AG investor presentation
Administration has additionally indicated that two extra CDMO molecules at present below improvement may every doubtlessly generate over Rs 100 crore in annual income as soon as commercialised in FY27.
That issues as a result of CDMO economics are basically totally different from customary intermediates. As soon as a provider turns into certified inside a pharmaceutical product chain, switching turns into troublesome resulting from regulatory and process-related dangers. This typically results in greater margins, longer buyer relationships, and higher income visibility.
As world pharma firms more and more outsource advanced chemistry work, Acutaas seems to be positioning itself immediately inside that structural development.
Story continues beneath this advert
The specialty chemicals enterprise: Battery supplies, semiconductors, and superb chemistry
The specialty chemicals section contributes 12% of FY26 income. It is additionally the place a lot of the market’s pleasure more and more resides, significantly round battery electrolyte components and semiconductor chemicals.
1. The battery electrolyte additive alternative
By means of its electrolyte components enterprise, Acutaas is positioning itself inside the world EV and energy-storage provide chain. The firm is constructing a large-scale facility at Jagadia, and administration lately acknowledged that the total 2,000 metric tonne capability every for FEC (Fluoroethylene Carbonate) and VC (Vinylene Carbonate) has already been booked for the subsequent three years.
FEC and VC are high-purity lithium-ion battery electrolyte components used to enhance battery stability and efficiency. The firm is additionally increasing into extra battery components, signalling ambitions past a single-product alternative.
Story continues beneath this advert
As EV adoption accelerates globally, battery provide chains are more and more seeking to diversify past China, and Acutaas seems to be positioning itself into that hole.
2. The semiconductor chemical alternative
The second main optionality inside specialty chemicals is semiconductors.
This chance is being pushed by means of Baba Superb Chem and the firm’s Korean JV by way of Indichem, centered on semiconductor-grade specialty chemicals the place qualification boundaries are extraordinarily excessive.
Administration has acknowledged that the analysis centre for the Korean JV is already operational, samples have began reaching potential clients, and the business plant is anticipated to be prepared by H2 CY2026.
The firm is additionally enterprise Rs 200 crore in capex for this initiative, with administration guiding for asset turns of almost 1x (implying potential income of roughly Rs 200 crore) together with excessive margin potential as soon as commercialisation scales.
The working leverage
Story continues beneath this advert
This is the place the funding thesis begins translating from narrative into numbers.
Over the previous few years, Acutaas’ income progress has remained sturdy, however EBITDA has grown even sooner. That divergence issues as a result of it suggests the enterprise is starting to profit from working leverage.
Supply: Acutaas Chemicals – Q4FY26 Investor presentation
Gross margins have additionally steadily improved, indicating a gradual shift towards higher-value merchandise and higher product combine. This is significantly essential in specialty chemicals, the place margin enlargement typically indicators enhancing pricing energy and rising contribution from advanced chemistry relatively than easy quantity progress.
Technique outlook
Supply: Firm concall Transcript of This fall FY26
The setup turns into significantly attention-grabbing as a result of a number of progress vectors may start scaling concurrently over the subsequent few years.
CDMO molecules are ramping up
Battery electrolyte components are getting into commercialisation
Semiconductor chemical initiatives are shifting towards buyer qualification and business scale
Medium-term income potential
Administration has guided that the CDMO enterprise may doubtlessly attain Rs 1,000 crore in income by FY28, whereas the semiconductor initiative is concentrating on almost Rs 200 crore in potential income over the medium time period.
The firm has additionally constructed 2,000 metric tonne capacities every for FEC and VEC in battery electrolyte components, with administration stating that the total capability has already been booked by a key buyer for the subsequent three years.
Rising enterprise verticals: Income and margins outlook
Supply: administration commentary in FY26
Acutaas is concurrently scaling CDMO, semiconductors, and battery chemicals collectively. That makes execution, commercialisation, and capital allocation the key variables to observe over the subsequent few years.
Valuations
At the present EV/EBITDA a number of of 44, the market is clearly not valuing Acutaas as a conventional pharma intermediate enterprise.
EV/EBITDA historic chart
Supply: http://www.screener.in
The premium possible displays 4 assumptions working in tandem:
- Semiconductor chemicals have gotten a significant long-term enterprise vertical
- Battery electrolyte components are being commercialised efficiently
- Pharma intermediates proceed to generate steady money flows
Additional working leverage driving margin enlargement as newer capacities scale
Only a few Indian chemical firms at present sit at the intersection of semiconductor localisation, battery supply-chain diversification, pharma outsourcing, and specialty chemistry.
Acutaas does.
And markets sometimes assign premium multiples to companies uncovered to a number of long-duration structural themes concurrently.
The larger query is not whether or not the alternatives are actual. They clearly are. The query is whether or not execution can maintain tempo with valuation. That is in the end what this funding thesis comes all the way down to.
Monetary knowledge has been sourced primarily from OneSource Specialty Pharma’s Q3 FY26 outcomes, earnings shows, regulatory filings, and publicly out there analysis as of April 2026.
Rahul Rao has helped conduct monetary literacy programmes for over 1,50,000 buyers. He additionally labored at an AIF, specializing in small and mid-cap alternatives.
Disclosure: The author or his dependents don’t maintain shares in the securities/shares/bonds mentioned in the article.
The web site managers, its worker(s), and contributors/writers/authors of articles have or could have an excellent purchase or promote place or holding in the securities, choices on securities or different associated investments of issuers and/or firms mentioned therein. The content material of the articles and the interpretation of information are solely the private views of the contributors/writers/authors. Traders should make their very own funding selections primarily based on their particular targets, assets and solely after consulting such unbiased advisors as could also be essential.
Source link
#Acutaas #Chemicals #specialty #chemicals #story #market #rerating #fast
